Intriguingly, several studies have shown that chronic treatment with the PAN-PDE4 inhibitor roflumilast reduces blood glucose levels in mouse models of obesity, suggesting a therapeutic potential for targeting PDE4 in diabetes [28,29]. This evidence concerns the gene PDE4A and obesity due to melanocortin 4 receptor deficiency.